FTC v. Enforma
This article was originally published in The Tan Sheet
Executive Summary
Supplement firm must remove from market all Fat Trapper Plus, Exercise in a Bottle products carrying certain weight-loss claims under a stipulated preliminary injunction entered Dec. 9 by Los Angeles federal Judge Spencer Letts. Court subsequently denied Enforma's request for stay of the injunction pending appeal. Enforma was hit with a similar preliminary injunction for its Chitozyme, Acceleron weight-loss products in October (1"The Tan Sheet" Nov. 4, 2002, In Brief). Civil contempt hearing is slated for Jan. 21 barring a settlement between Enforma, FTC...
You may also be interested in...
FTC v. Enforma
Supplement firm preliminarily enjoined from making certain weight-loss claims for Chitozyme and Acceleron under Los Angeles federal Judge Spencer Letts' Oct. 30 order. FTC says Enforma must recall, repackage and relabel products while also ensuring vendors are in compliance. Enforma is seeking stay of the preliminary injunction pending appeal. FTC now is expected to seek similar injunctive relief for Enforma's Fat Trapper Plus and Exercise In A Bottle. Court's order stems from FTC's July 23 civil contempt motion (1"The Tan Sheet" Aug. 5, 2002, p. 5)...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.